United Therapeutics Corp. (NASDAQ:UTHR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On February28, 2019, the Board of Directors of United Therapeutics Corporation (the “Company”), acting upon the recommendation of its Compensation Committee, adopted the United Therapeutics Corporation 2019 Inducement Stock Incentive Plan (the “Plan”) to allow the grant to prospective employees of equity incentives that qualify as “inducement” awards under Nasdaq rules.
The objective of the Plan is to allow the Company to grant equity award to prospective employees in order to stimulate the efforts of those employees by heightening their desire to work toward and contribute to the success and progress of the Company. The Plan will be administered by the Compensation Committee. The Compensation Committee will, subject to the terms of the Plan, have all authority to determine the recipients of Plan awards and to determine the terms and conditions of any such awards. The following briefly describes the material features of the Plan:
· Shares Available for Grant: 99,000 shares of Company common stock have been reserved for issuance under the Plan, subject to adjustment for stock dividends, stock splits, or other changes in the Company’s common stock or the Company’s capital structure; provided that any shares granted under options or stock appreciation rights will be counted against this limit on a one-for-one basis and any shares granted as awards other than options or stock appreciation rights will be counted against this limit as 2.14 shares for every one (1)share subject to such award.
· Eligibility. An individual is eligible to receive an award under the Plan if he or she is a prospective new employee of the Company. Awards under the Plan must be a material inducement for the prospective employee to accept employment with the Company or a subsidiary.
· Types of Awards. Under the Plan, the Compensation Committee may choose to grant nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, and stock awards to eligible participants.
· Terms of Options and Stock Appreciation Rights. The exercise price of all stock options and stock appreciation rights granted under the Plan will be determined by the Committee but must be at least equal to 50% of the fair market value of the covered common stock on the date of grant. The term, vesting schedule, and other conditions applicable to stock options and stock appreciation rights will be established by the Committee at the time of grant.
· Terms of Restricted Stock, Restricted Stock Units and Stock Awards. These awards will become vested or earned by recipients based on employment (time-based) requirements, performance-based vesting or other conditions as the Committee may determine. Awards of restricted stock and stock awards will be actual shares of outstanding Company common stock and unless otherwise determined by the Committee, will have the same voting, dividend, and other rights as other shares of common stock. Awards of restricted stock units represent unsecured obligations on the part of the Company, and no shares will be issued in respect of these awards unless and until the award vests.
· Term and Amendment of the Plan. The Plan will remain in effect until terminated by the Board. The Board has the authority to amend or terminate the Plan at any time and for any reason.
· NASDAQ Compliance. The Inducement Plan is intended to comply with Nasdaq Rule5635(c)(4), which permits the granting of equity compensation awards without shareholder approval as a material inducement to individuals entering into employment with the Company.
This summary of the Plan is qualified in its entirety by the terms of the Plan. A copy of the Plan and the form of Restricted Stock Unit grant notice and standard terms and conditions under the Plan are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form8-K and are incorporated by reference herein.
UNITED THERAPEUTICS Corp Exhibit
EX-10.1 2 a19-4992_2ex10d1.htm EX-10.1 Exhibit 10.1 UNITED THERAPEUTICS CORPORATION 2019 INDUCEMENT STOCK INCENTIVE PLAN 1. Purpose The purpose of the United Therapeutics Corporation 2019 Inducement Stock Incentive Plan (this Plan) is to advance the interests of United Therapeutics Corporation (the Company) by enabling the Company to grant awards to individuals who have not previously been employees or non-employee directors of the Company (or who have had a bona fide period of non-employment with the Company) to induce them to accept employment with the Company. Grants of such awards are intended to stimulate the efforts of such individuals by heightening the desire of such individuals to work toward and contribute to the success and progress of the Company. This Plan provides for the grant Nonqualified Stock Options,…
To view the full exhibit click here
About United Therapeutics Corp. (NASDAQ:UTHR)
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). Its Prostacyclin Analogues lead product is Remodulin (treprostinil) Injection. It also includes Tyvaso (treprostinil) Inhalation Solution and Orenitram (treprostinil) Extended-Release Tablets. Its subsidiary is developing another oral prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) called esuberaprost. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets are indicated for the treatment of PAH. Its Unituxin (dinutuximab) Injection in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid is indicated for the treatment of pediatric patients with neuroblastoma.